Completed PHASE3 INTERVENTIONAL 2-arm NCT01948830

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration

Sponsor: Novartis Pharmaceuticals

Conditions Age-related Macular Degeneration Choroidal Neovascularization

Interventions Ranibizumab 0.5mg

Updated 7 times since 2017 Last updated: Mar 16, 2017 Started: Dec 17, 2013 Primary completion: Nov 19, 2015 Completion: Nov 19, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Age-related Macular Degeneration and Choroidal Neovascularization and is currently completed. Novartis Pharmaceuticals leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2017 [monthly]

Completed PHASE3

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahaus, Germany , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Augsburg, Germany , Bangalore, India , Banská Bystrica, Slovakia , Barcelona, Spain , Belfast, United Kingdom , Bern, Switzerland , Bratislava, Slovakia and 67 more locations